ArticleUrolithiasis2025
Retrograde pyeloperfusion: a novel technique to prevent stone fragment migration into the ureter during percutaneous nephrolithotomy.
Article in Urolithiasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To determine whether retrograde pyeloperfusion (RP) during percutaneous nephrolithotomy (PCNL) decreases antegrade ureteral stone fragment migration, normal, moderately, and severely hydronephrotic silicone kidney and ureter models were created using deidentified CT images. Two techniques to prevent fragment migration, ureteral access sheath (UAS) and RP via a ureteroscope, were compared to an empty ureter. Two grams of stone fragments were placed into the renal pelvis. Antegrade irrigation and suction were applied for 5 min. The weights of ureteral stone fragments were compared using the Kruskal-Wallis test (p < 0.05 significant). In the normal ureter model, RP significantly reduced ureteral stone fragment migration (0.06±0.03 g) compared to both the UAS (0.32±0.19 g; p = 0.047) and control (0.42±0.11 g; p = 0.009). Similarly, in the moderate hydroureter model, RP significantly reduced ureteral stone fragment migration (0.11±0.06 g) compared to both the UAS (0.68±0.18 g; p = 0.009) and control (0.48±0.15 g; p = 0.016). In the severe hydroureter model, RP reduced ureteral stone fragment migration (0.17±0.12 g) compared to the UAS (1.04±0.29 g; p = 0.026) but was similar to the control (0.65±0.37 g; p = 0.169). RP showed an 85.7% and 81.1% reduction compared to the control and UAS conditions in the normal model, 76.2% and 83.3% reduction in the moderate hydroureter model, and 73.3% and 83.2% reduction in the severe hydroureter model, respectively. Thus, compared to an empty ureter and a UAS, in all ureter models, RP reduced ureteral stone fragment migration by 73.3-85.7%. Retrograde pyeloperfusion should be considered to reduce ureteral stone fragment migration during PCNL when endoscopic combined intrarenal surgery is employed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.